Perpetrator effects of ciclosporin (P‐glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers-Reference-Cited by-同舟云学术

Perpetrator effects of ciclosporin (P‐glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers

Published:2019-05-09 Issue:7 Volume:85 Page:1528-1537
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Brings Antonia¹,Lehmann Marie‐Louise¹,Foerster Kathrin I.¹,Burhenne Jürgen¹,Weiss Johanna¹^ORCID,Haefeli Walter E.¹^ORCID,Czock David¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology and PharmacoepidemiologyUniversity of Heidelberg Heidelberg Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13934

Reference41 articles.

1. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

2. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

3. EMA summary of product characteristics last updatedJuly 2018(http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 3 September 2018.

4. FDA drug label of Xarelto last updated February2017.https://dailymed.nlm.nih.gov/dailymed/. Accessed 3 September 2018.

5. In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Danhong Injection on Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Rats;2024-08-19

2. Mechanistic Account of Distinct Change in Organic Anion Transporting Polypeptide 1B (OATP1B) Substrate Pharmacokinetics during OATP1B-Mediated Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling;Drug Metabolism and Disposition;2024-05-13

3. Effect of Diosmin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Rats;Current Pharmaceutical Analysis;2024-05

4. The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review;European Journal of Drug Metabolism and Pharmacokinetics;2024-04-30

5. Effects of Triazole Antifungal Agents on the Plasma Concentration and Dosage of Cyclosporin in Patients with Aplastic Anaemia;Journal of Clinical Pharmacy and Therapeutics;2024-02-27